GNFTF - Cirius Therapeutics Seeks $86 Million IPO
Quick Take
Cirius Therapeutics (CSTX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm provides is developing small-molecule treatments for nonalcoholic steatohepatitis [NASH] with fibrosis.
CSTX has seen promising results in Phase 2b trials for its drug candidate.
Company & Technology
San Diego, California-based Cirius Therapeutics was founded in 2015 to develop small molecule pharmaceuticals for the treatment of NASH while addressing the commonly associated negative side effects observed with other types of thiazolidinediones [TZDs].
Management is headed by CEO Robert